Bromfenac (Duract)-associated hepatic failure requiring liver transplantation.
作者信息
Hunter E B, Johnston P E, Tanner G, Pinson C W, Awad J A
机构信息
Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232-2279, USA.
出版信息
Am J Gastroenterol. 1999 Aug;94(8):2299-301. doi: 10.1111/j.1572-0241.1999.01321.x.
Abstract
Bromfenac sodium (Duract) is a phenylacetic acid-derived nonsteroidal anti-inflammatory agent introduced in the United States in 1997 and withdrawn in 1998. We describe the first case of fulminant hepatic failure associated with this agent treated successfully with liver transplantation. Similarities to hepatotoxicity with related agents is discussed.
摘要
Zotero 插件